Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ziconotide

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,402,310Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tersera Notes PACC Guidelines Update For PRIALT Administration
    Tersera Notes PACC Guidelines Update For PRIALT Administration

    23 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240723453532/en

    BUSINESSWIRE
    23 Jul 2024
    Share Share
    AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics
    AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics

    20 Jul 2021

    // PRESS RELEASE

    https://www.ambiopharm.com/news-press/ambiopharm-inc-working-with-university-of-california-davis-to-develop-non-opioid-peptide-based-pain-therapeutics/

    PRESS RELEASE
    20 Jul 2021
    Share Share
    Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics for Prialt
    Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics for Prialt

    29 Jun 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-enters-into-agreement-with-tersera-therapeutics-llc-for-prialt-300674775.html

    PR NEWSWIRE
    29 Jun 2018
    Share Share